Topics

BCMA-Targeted CAR-T for MM

Cancer Immunotherapy Tumor Microenvironment Cellular Stress Cell Programmed Death

B-cell maturation antigen is a highly relevant surface target on malignant plasma cells, making BCMA-directed CAR-T therapy a major advance for relapsed or refractory multiple myeloma. BCMA supports plasma-cell survival through ligands such as APRIL and BAFF and is more restricted to the B-cell lineage than many alternative targets. Autologous BCMA CAR-T products can induce deep responses after multiple prior therapies, including in disease resistant to proteasome inhibitors, immunomodulatory drugs, and antibodies. Relapse remains common, so research has shifted from initial response toward durability, sequencing, and salvage. The marrow microenvironment, antigen evolution, and quality of manufactured T cells all influence long-term control Clinical development followed earlier evidence from BCMA-directed antibodies and established the antigen as both a therapeutic handle and a marker of plasma-cell biology[1][2][3].

The CAR binds BCMA independently of MHC and activates CD3ζ plus costimulatory signaling, leading to plasma-cell killing, cytokine release, expansion, and potential memory formation. Lymphodepletion supports post-infusion expansion. Resistance can arise through low BCMA density, antigen downregulation or loss, soluble BCMA, selection of resistant clones, impaired death pathways, or insufficient CAR persistence. Repeated stimulation and inhibitory marrow signals promote exhaustion, while stromal and myeloid cells provide survival support to residual myeloma. A deep clinical response can therefore coexist with small resistant populations that later repopulate marrow or extramedullary sites CAR architecture and manufacturing influence expansion and persistence, so two BCMA products cannot be assumed to share identical kinetics or resistance profiles[1][3].

Clinical use requires collection, bridging treatment, lymphodepletion, infusion, and monitoring for cytokine release syndrome, neurotoxicity, cytopenia, infection, and hypogammaglobulinemia. Delayed neurologic and hematologic effects require product-specific follow-up. At relapse, reassessing BCMA and disease distribution guides salvage. BCMA-retained disease may respond to another BCMA modality, but prior exposure, interval, and T-cell fitness matter. Antigen-low disease motivates targets such as GPRC5D, dual-target CARs, bispecific antibodies, or non-cellular therapy. Earlier use may capture fitter T cells, yet it must be compared with effective standard combinations and account for manufacturing access Because normal plasma cells also express BCMA, effective therapy predictably impairs humoral immunity and may require vaccination planning, prophylaxis, or immunoglobulin replacement[1][2][3].

Future development should prioritize prevention and classification of relapse. Dual-target recognition, optimized costimulation, memory-preserving manufacturing, allogeneic platforms, and armored cells may improve durability. Serial marrow, blood, and extramedullary sampling should measure antigen density, soluble BCMA, CAR kinetics, clonality, and immune state. Minimal residual disease can refine response assessment but must be linked to sustained progression-free and overall survival. Trials should define sequencing among CAR-T cells, bispecific antibodies, antibody-drug conjugates, and transplantation. BCMA CAR-T therapy has transformed late-line myeloma, but its next gains will depend on maintaining immune surveillance and selecting timely, mechanism-matched therapy when the tumor escapes Real-world studies should include older, frail, renally impaired, and extramedullary-disease populations who may be underrepresented in registration trials yet frequently need treatment. Resistance-guided salvage should be planned before infusion so that target testing, referral, and an alternative therapy are available at progression. Access improvements must reduce manufacturing failure and treatment delay without weakening rigorous long-term patient safety surveillance[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-11109 Resatorvid
Resatorvid (TAK-242) is a selective Toll-like receptor 4 (TLR4) inhibitor. Resatorvid inhibits NO, TNF-α and IL-6 production with IC50s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy and plays pivotal role in various inflammatory diseases.
Toll-like Receptor (TLR)   TNF Receptor   Interleukin Related   Autophagy  
Prostate Cancer   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
536
HY-15924 Thiazolyl Blue
Thiazolyl Blue (MTT) is a cell-permeable and positively charged tetrazolium dye that is used to detect reductive metabolism in cells. Thiazolyl Blue is taken up by cells through the plasma membrane and then reduced to formazan by intracellular NAD (P) H-oxidoreductases. Thiazolyl Blue is frequently used in colorimetric assays to measure cell proliferation, cytotoxicity, and apoptosis.
Fluorescent Dye  
194
HY-100573 Necrosulfonamide
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
Mixed Lineage Kinase   Necroptosis   Pyroptosis   Caspase   NOD-like Receptor (NLR)   Keap1-Nrf2   TNF Receptor   Interleukin Related   NO Synthase   Heme Oxygenase (HO)  
Digestive System Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Depression   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
147
HY-N0322A Cholesterol (Water Soluble)
Cholesterol Water Soluble is a major sterol in mammals, constituting 20-25% of the structural composition of the plasma membrane. The plasma membrane is highly permeable to water but relatively impermeable to ions and protons. Cholesterol Water Soluble plays an important role in determining the fluidity and permeability characteristics of membranes and the function of transporters and signaling proteins. Cholesterol Water Soluble is also an endogenous estrogen-related receptor alpha (ERRα) agonist. Cholesterol Water Soluble can be used to study the effects of cholesterol on potassium currents in inner hair cells.
(Note: This product is a mixture of Cholesterol and Methyl-β-cyclodextrin. The product specifications below only indicate the effective content of Cholesterol.)
Liposome  
Atherosclerosis   Hypercholesterolemia  
95
HY-L053 NMPA-Approved Drug Library
From target identification to clinical research, traditional drug discovery and development is a time-consuming and costly process, which also bears high risk. Compared with traditional drug discovery, drug repositioning or repurposing, also known as old drugs for new uses can greatly shorten the development cycle and reduce development cost, which has become a new trend of drug development. After undergoing clinical trials, approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety, which can greatly improve the success rate of drug discovery. A number of successes have been achieved, such as metformin for type 2 diabetes and thalidomide for leprosy and multiple myeloma, etc. MCE provides a unique collection of 1,534 China NMPA (National Medical Products Administration) approved compounds, which have undergone extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE NMPA-Approved Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.

Drug Repurposing Series

84
HY-L182 Fatty Acids Compound Library
Fatty acids (FAs) are the main components of lipids. The synthesis of fatty acids mainly involves the Triglyceride (TG) cycle and De Novo Lipogenesis (DNL). Fatty acids which exist widely in organisms are components of cell membranes and play an indispensable role in cell signaling. In addition, FFAs can be taken up from circulating plasma by all mitochondria-containing cells, and they are metabolized by β-oxidation and the citric acid cycle to release large amounts of energy in the form of ATP. Abnormal fatty acid metabolism is associated with the occurrence and development of cardiovascular diseases, diabetes, fatty liver, hyperthyroidism, and other diseases. MCE offers a unique collection of fatty acid compounds. Fatty Acids Compound Library is an important tool for the study of energy metabolism and drug development of metabolism-related diseases.

Structure Classified Libraries

84
HY-L118 Sodium Channel Blocker Library
Sodium channels conduct sodium ions (Na+) through a cell's plasma membrane that are the source of excitatory currents for the nervous system and muscle. Na channels are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). Dysfunction in voltage-gated sodium channels correlates with neurological and cardiac diseases, including epilepsy, myopathies, pain and cardiac arrhythmias. Sodium channel blockers are used in the treatment of cardiac arrhythmia, pain and convulsion. MCE offers a unique collection of 199 sodium channel blocker and antagonists, all of which have the identified inhibitory effect on sodium channels. MCE Sodium Channel Blocker Library can be used for neurological and cardiac diseases drug discovery and sodium channel research.

Signaling Pathway Targeting Libraries

83
HY-L140 Withdrawn Drug Compound Library
Withdrawal or delisting drugs refer to drugs that are recalled or discontinued from the market due to low efficiency, serious side effects, financial and regulatory problems and other reasons. Once the drug is withdrawn from the market, it will cause heavy losses to the original research company that invested a lot of time, finance and other costs to develop the drug. Adverse drug reaction (ADR) is the main reason for drug withdrawal from the market. ADR refers to the unexpected effects caused by the reasons such as the target-directed interaction during the treatment. However, studying the mechanism of these ADRs may just be a breakthrough in finding new indications. For example, thalidomide, the protagonist of the drug damage event that caused numerous "seal babies" deformed infants, was found to be due to the degradation of a transcription factor - SALL4 after delisting, which made thalidomide have a new clinical application. In 1998, it was approved by FDA for the treatment of leprosy nodular erythema, and in 2006, it was approved for the treatment of multiple myeloma. ADR study of delisted drugs can not only avoid the loss of drug development in advance but also bring hope to new indications. MCE has sorted out 232 drug compounds withdrawn from the market through FDA, EMA and other authoritative platforms. Each compound has withdrawal records in at least one country/market. It is a useful tool for conducting research on drug side effects or drug toxicity mechanisms and discovering new indications of drugs.

Drug Repurposing Series

83
HY-L150 Membrane Receptor-targeted Compound Library
Membrane receptors, also known cell surface receptors or transmembrane receptors, are transmembrane proteins embedded into the plasma membrane which play an essential role in maintaining communication between the internal processes within the cell and various types of extracellular signals. They act in cell signaling by receiving (binding to) extracellular molecules, which are also called ligands. These extracellular molecules include hormones, cytokines, growth factors, neurotransmitters, lipophilic signaling molecules such as prostaglandins, and cell recognition molecules. There are three kinds of membrane receptors: ion channel-linked receptors, enzyme-linked receptors and G-protein-linked receptors. They play important roles in keeping human normal physiologic processes. GPCRs and ion channels are important drug targets in drug discovery. MCE provides a unique collection of 7,133 compounds targeting a variety of membrane receptors. MCE Membrane reeptor-targeted Compound Library can be used for membrane receptor-focused screening and drug discovery.

Signaling Pathway Targeting Libraries

83
HY-L168 Extracellular Vesicles (EVs) Compound Library
Extracellular vesicles (EVs) are small membrane binding structures that are released from cells into the surrounding environment and play a crucial role in mediating and regulating intercellular communication related to physiological and pathological processes. EVs are lipid membrane vesicles composed of proteins, lipids, and nucleic acids. EVs can be divided into several types based on their source, such as extracellular vesicles, microcapsules, and apoptotic vesicles. The size range of exosomes is 30-150nm, which are endocrine in multi vesicular endosomes (MVEs); microvesicles (50-1000nm) are secreted directly through extracellular interactions, thereby releasing plasma membrane vesicles. In contrast, apoptotic bodies are usually larger, ranging in size from 1 to 5 μ m. This is generated during programmed cell death. EV plays a crucial role in transmitting information between cells and influencing the behavior and function of receptor cells. MCE designs a unique collection of 707 small molecules related to extracellular vesicles (EVs). It is a good tool to be used for research on metabolize, cancer and other diseases.

Signaling Pathway Targeting Libraries

83
HY-L924 Boronic acid/boronic ester fragment library
Boronic acid and boronic ester represent a relatively novel and promising chemical structure in drug design. Boronic acid exists in an sp²-hybridized state, possessing an empty p-orbital that can act as a Lewis acid to accept lone pairs from heteroatoms (O, N, or S). This Lewis acidity enables it to form reversible covalent bonds with amino acid residues such as lysine, serine, threonine, and histidine. Currently, five FDA-approved drugs containing boronic acid or boronic ester predominantly involve such covalent binding mechanisms in their interactions with target proteins. Furthermore, boronic acid can serve as a bioisostere for carboxylic acids, phosphates, and phenolic groups, utilized to improve pharmacokinetic properties and enhance drug efficacy. To date, five boron-containing drugs have been approved by the FDA. The unique properties of boronic acids and boronic esters confer significant potential in drug design, with applications spanning cancer therapy (e.g., multiple myeloma), anti-infectives (e.g., fungal infections, tuberculosis), anti-inflammatory treatments (e.g., atopic dermatitis), antibacterial agents (e.g., carbapenem-resistant bacterial infections), and Reactive Oxygen Species (ROS)-responsive prodrugs, among others. The MCE Boronic Acid/Boronic Ester Fragment Library, which contains 1,488 compounds, serves as a valuable tool for the development of boron-containing drugs.

According to Fragment Structures

83
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-N0822 Shikonin
Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC50 of 6.5 μM. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor and can also inhibit TNF-α and NF-κB pathway. Shikonin decreases exosome secretion through the inhibition of glycolysis. Shikonin inhibits AIM2 inflammasome activation.
Exosomes   Chloride Channel   Pyruvate Kinase   NF-κB   TNF Receptor   HIV   AIM2  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Depression   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
74
HY-A0003 Lenalidomide
Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8+ T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury.
Molecular Glues   Ligands for E3 Ligase   IKZF Family   Casein Kinase   Apoptosis   Pyroptosis   MDM-2/p53   TNF Receptor  
Inflammation or Immune System Disease   Renal Disease   Chronic Lymphocytic Leukemia   Diffuse Large B-cell Lymphoma   Multiple Myeloma   Myelodysplastic Syndrome   Liver Failure  
63
HY-N0176 Dihydroartemisinin
Dihydroartemisinin is an orally active metabolite of rtemisinin (HY-B0094) and antimalarial agent. Dihydroartemisinin induces Autophagy by inhibiting NF-κB activation. Dihydroartemisinin promotes ROS accumulation. Dihydroartemisinin exhibits anticancer activity in esophageal cancer cells. Dihydroartemisinin shows schistosomicidal activity against juvenile and adult worms of Schistosoma japonicum, reduces worm burden, and displays antiparasitic activity. Dihydroartemisinin can be used in research related to multiple myeloma, promyelocytic leukemia, esophageal cancer, and Schistosoma japonicum infection.
Parasite   NF-κB   Autophagy   Reactive Oxygen Species (ROS)   Drug Metabolite  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Parasitic Infection   Depression   Pain   Digestive System Inflammation   Obesity  
45
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-N0182 Fisetin
Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.
Sirtuin   PPAR   TNF Receptor  
Digestive System Disease   Prostate Cancer   Viral Infection   Depression   Digestive System Inflammation   SARS-CoV-2 Infection   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
35
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-P9970 Infliximab
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.
The component ratio of this product is Active ingredient : Excipients = 9 : 47.

Species: Human

TNF Receptor  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Lung Cancer   Breast Cancer  
30
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-B0633A Hyaluronic acid
Hyaluronic acid is a biopolymer composed of repeating units of disaccharides with various applications. Hyaluronic acid is a major component of the extracellular matrix (ECM). Hyaluronic acid is synthesized at the plasma membrane. Increased hyaluronic acid levels are associated with tumor cell growth, adhesion, migration, invasion and angiogenesis in digestive cancers. Hyaluronic acid participates in tissue remodeling and rapid cell proliferation in some physiological processes including embryonic morphogenesis and wound-healing. Hyaluronic acid activates the PI3K-Akt signaling. Hyaluronic acid acts as a regulator of cancer-associated lymphangiogenesis. Hyaluronic acid also enhances cell invasion and angiogenesis by promoting proteolytic MMP-9 binding to cell surface or stimulating MMP-9 binding to cell surface. Hyaluronic acid can be used as drug delivery for sodium butyrate to improve the anti-proliferative activity on breast cancer cell line. Hyaluronic acid can be studied in joint diseases, wound healing and cancer.
Endogenous Metabolite   Bacterial   Akt   PI3K  
Breast Cancer   Prostate Cancer   Pancreatic Cancer   Bacterial Infection   Depression   Pain   Digestive System Inflammation   SARS-CoV-2 Infection  
21
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-P9908 Adalimumab
Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).

Species: Human

TNF Receptor   Bacterial  
Cancer   Autoimmune Disease  
20
HY-P1846 Jagged-1 (188-204)
Jagged-1 (188-204) is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells.
Notch  
Cancer  
19
HY-P1846A Jagged-1 (188-204) TFA
Jagged-1 (188-204) TFA is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells.
Notch  
Cancer  
19
HY-Y0966 Glycine
Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine inhibits the membrane aggregation of NINJ1 and prevents plasma membrane rupture during cell death. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis.
Ninjurin   Endogenous Metabolite   VEGFR   PROTAC Linkers   iGluR  
Colorectal Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Schizophrenia   Pain   Non-Small Cell Lung Cancer   HER-2 Positive Breast Cancer   Multiple Myeloma   HSV Infection   SARS-CoV-2 Infection   Alzheimer's Disease   Lung Fibrosis  
18
HY-K0311 GSH/GSSG Assay Kit

MCE GSH/GSSG Assay Kit is suitable for the quantitative determination of reduced and oxidized glutathione (GSH/GSSG) in whole blood, plasma, serum, urine, and tissue and cell extracts.

Cell Biology Cell Analysis Metabolism Assay Kit

17
HY-108847 Etanercept
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.
TNF Receptor   Bacterial  
Cancer   Rheumatoid Arthritis  
16
HY-D0986 TMA-DPH
TMA-DPH is a hydrophobic fluorescent membrane probe (Ex=355 nm; Em=430 nm). TMA-DPH is able to anchor on the cell surface and localize to different regions of the phospholipid bilayer. By analyzing the fluorescence polarization values of TMA-DPH in the plasma membrane and membrane substructures, the fluidity of the cell membrane can be determined.
Fluorescent Dye  
11
HY-K0319 Lipid Peroxidation (MDA) Assay Kit

MCE Lipid Peroxidation (MDA) Assay Kit is suitable for measuring MDA levels in a variety of samples including plasma, serum, urine, tissues or cell lysates.

Cell Biology Cell Analysis Metabolism Assay Kit

10
HY-107632 GYY4137
GY4137 is a sustained-release H2S donor possessing vasodilatory, antihypertensive, and anti-inflammatory activities. GY4137 can inhibit cell growth, induce apoptosis, and cause cell cycle arrest by blocking the STAT3 pathway, demonstrating potent anticancer activity.
Apoptosis   STAT   NF-κB   NO Synthase   COX   TNF Receptor   Interleukin Related  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
8
HY-N0815 Resibufogenin
Resibufogenin is an orally active anticancer agent. Resibufogenin can be extracted from toad venom. Resibufogenin blocks signaling pathways such as PI3K/Akt, NF-κB, AP-1, activates GSK-3β, and regulates cyclin D1. Resibufogenin can activate central neurons. Resibufogenin has anti-inflammatory activity. Resibufogenin has anti-tumor effects on a variety of tumors such as multiple myeloma, renal cancer, colorectal cancer, pancreatic cancer, and glioma.

Source: toad

PI3K   Akt   NF-κB   AP-1   GSK-3   CDK  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
7
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-16050 Plitidepsin
Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( KD=80 nM). Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC90 of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research.

Source: Mediterranean tunicate Aplidium albicans

DNA/RNA Synthesis   SARS-CoV  
6
HY-P99459 Baminercept
Baminercept (BG 9924; TT-47) is an Ig fusion protein targeting the lymphotoxin β receptor (LTβR). Baminercept effectively regulates subsets of circulating immune cells by inhibiting LIGHT, LT-α1β2 and their receptors. Baminercept also increases blood lymphocyte counts and reduces plasma CXCL13 levels. Baminercept carries a high risk of hepatotoxicity. Baminercept can be used in research on rheumatoid arthritis and primary Sjögren's syndrome.
TNF Receptor   CXCR  
Rheumatoid Arthritis  
3
HY-P9980 Belantamab
Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma.

Species: Human

ADC Antibodies   TNF Receptor  
Multiple Myeloma  
3
HY-156404 PM-1
PM-1, a derivative of Thioflavin-T (ThT; HY-D0218), is a small but highly specific plasma membrane (PM) fluorescent dye for specific and long-time membrane imaging of living and fixed cells. PM-1 is embedded directly into the cell membrane and exhibits a very long retention time on the plasma membrane with a half-life of approximately 15 h. PM-1 can be used in combination with protein labeling probes to study ectodomain shedding and endocytosis processes of cell surface proteins.
Fluorescent Dye  
2
HY-114297 Zymosterol
Zymosterol is a Cholesterol (HY-N0322) biosynthesis metabolite. Zymosterol, a precursor of Cholesterol, is found mostly in the plasma membrane. Zymosterol circulates within the cell.

Source: yeast-fat

Endogenous Metabolite  
Metabolic or Endocrine Disease  
2
HY-P5712 Gramicidin S
Gramicidin S (Gramicidin soviet) is a cationic cyclic peptide antibiotic that selectively targets bacterial cell membranes and has anticancer activity. Gramicidin S also exerts antibacterial activity by destroying membrane integrity and interfering with membrane protein function. Gramicidin S inserts into the phospholipid bilayer through hydrophobic amino acid residues, specifically binds to negatively charged membrane lipids and disrupts membrane structure, thereby inhibiting cell division and cell wall synthesis, and ultimately causing bacterial death. Gramicidin S also inhibits ion channels, with IC50s of 41 μM, 24 μM, and 3 μM for Na+/K+-ATPase, tobacco leaf plasma membrane Mg2+/K+-ATPase, and rat heart plasma membrane Ca2+-ATPase, respectively.
Antibiotic   Bacterial   Na+/K+ ATPase  
Bacterial Infection  
2
HY-124171 Zinquin ethyl ester
Zinquin ethyl ester is a cell-permeable and lipophilic fluorescent derivative of Zinquin (HY-D0982). Zinquin ethyl ester reacts with protein-bound Zn2+ in cells and forms fluorescent ternary adducts. Zinquin ethyl ester undergoes hydrolysis by intracellular esterases impeding its efflux across the plasma membrane (Ex/Em = 370/470 nm).
Fluorescent Dye   Drug Derivative  
2
HY-K2001 Bradford Protein Assay Kit

MCE Bradford Protein Assay Kit is suitable for detecting the total protein content in samples such as serum, plasma, animal tissues, and cells.

Protein Biology Protein Sample Preparation Protein Assay

2
HY-105019 Melflufen
Melflufen (Melphalan flufenamide), a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen shows antitumor activity against multiple myeloma (MM) cells and inhibits angiogenesis. Melflufen induces irreversible DNA damage and cytotoxicity in MM cells.
DNA Alkylator/Crosslinker   Apoptosis  
Cancer  
1
HY-N0667S5 L-Asparagine-d3 hydrate
L-Asparagine-d3 hydrate is the deuterium labeled L-Asparagine (HY-N0667). L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Inflammation or Immune System Disease  
1
HY-P99400 Samalizumab
Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research.

Species: Human

Others  
Cancer  
1
HY-12664 AF64394
AF64394 is a GPR3 inverse agonist, with a pIC50 of 7.3.
Orphan GPCR  
1
HY-N0667S2 L-Asparagine-15N2 monohydrate
L-Asparagine-15N2 monohydrate is the 15N-labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Inflammation or Immune System Disease  
1
HY-160187 AAA
AAA is an orally active 20-HETE receptor antagonist. AAA exerts antihypertensive and organoprotective effects. AAA blocks 20-HETE prohypertensive actions, suppresses intrarenal and circulating angiotensin II levels, and interferes with renin-angiotensin system interactions. AAA attenuates development of, and reverses established, ANG II (HY-13948)-dependent malignant hypertension. AAA reduces albuminuria, glomerulosclerosis, and cardiac hypertrophy linked to malignant hypertension. AAA can be used for the research of malignant hypertension.
Orphan GPCR   Angiotensin Receptor  
Hypertension  
1
HY-D1056B3 Lipopolysaccharides, from Klebsiella pneumoniae
Lipopolysaccharides, from Klebsiella pneumoniae (LPS, from bacterial (Klebsiella pneumoniae)) are lipopolysaccharide endotoxins and TLR4 activators derived from Klebsiella pneumoniae, and are classified as S-type LPS. Lipopolysaccharides, from Klebsiella pneumoniae exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from Klebsiella pneumoniae may participate in bacterial immune evasion by inhibiting complement-mediated killing and suppressing the host's secretion of antimicrobial peptides, thereby allowing the bacteria to escape immune defenses. Lipopolysaccharides, from Klebsiella pneumoniae possess high viscosity and resistance to serum-mediated killing, which may lead to sepsis. Lipopolysaccharides, from Klebsiella pneumoniae can be used to construct Acute Lung Injury Model.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P990007 Tulisokibart
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis.

Species: Human

TNF Receptor  
Digestive System Inflammation   Crohn's Disease   Ulcerative Colitis  
1
HY-N0176S3 Dihydroartemisinin-d5
Dihydroartemisinin-d5 (Dihydroqinghaosu-d5) is the d5-labeled Dihydroartemisinin (HY-N0176). Dihydroartemisinin is an orally active metabolite of rtemisinin (HY-B0094) and antimalarial agent. Dihydroartemisinin induces Autophagy by inhibiting NF-κB activation. Dihydroartemisinin promotes ROS accumulation. Dihydroartemisinin exhibits anticancer activity in esophageal cancer cells. Dihydroartemisinin shows schistosomicidal activity against juvenile and adult worms of Schistosoma japonicum, reduces worm burden, and displays antiparasitic activity. Dihydroartemisinin can be used in research related to multiple myeloma, promyelocytic leukemia, esophageal cancer, and Schistosoma japonicum infection.
Isotope-Labeled Compounds   Parasite   NF-κB   Autophagy   Reactive Oxygen Species (ROS)   Drug Metabolite  
Breast Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Multiple Myeloma   Plasmodium Infection   Systemic Lupus Erythematosus   Obesity  
/
HY-N0176S Dihydroartemisinin-d3
Dihydroartemisinin-d3 (Dihydroqinghaosu-d3) is the d3-labeled Dihydroartemisinin (HY-N0176). Dihydroartemisinin is an orally active metabolite of rtemisinin (HY-B0094) and antimalarial agent. Dihydroartemisinin induces Autophagy by inhibiting NF-κB activation. Dihydroartemisinin promotes ROS accumulation. Dihydroartemisinin exhibits anticancer activity in esophageal cancer cells. Dihydroartemisinin shows schistosomicidal activity against juvenile and adult worms of Schistosoma japonicum, reduces worm burden, and displays antiparasitic activity. Dihydroartemisinin can be used in research related to multiple myeloma, promyelocytic leukemia, esophageal cancer, and Schistosoma japonicum infection.
Isotope-Labeled Compounds   Parasite   NF-κB   Autophagy   Reactive Oxygen Species (ROS)   Drug Metabolite  
Breast Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Multiple Myeloma   Plasmodium Infection   Systemic Lupus Erythematosus   Obesity  
/
HY-179475 KP-2067
KP-2067 is a form of the CaSR agonist peptide. KP-2067 can result in dose-dependent activation of CaSR in HEK293T overexpressing hCaSR cell line, with an EC50 of 18.4 μM. KP-2067 significantly reduces plasma parathyroid hormone in rat model.
CaSR  
/
HY-P4078 (Arg)9 biotin labeled
(Arg)9 biotin labeled is a cell-permeable peptide. (Arg)9 biotin labeled can be used for drug delivery. (Arg)9 biotin labeled can traverse the plasma membrane of eukaryotic cells.
Others  
/
HY-P10649 CPP12
CPP12 is a small, amphipathic, cyclic cell-penetrating peptide (CPP). CPP12 binds directly to plasma membrane phospholipids, enters mammalian cells via endocytosis, and then efficiently escapes from endosomes. CPP12 can be used for the intracellular delivery of drugs and chemical probes.
Others  
Cancer  
/
HY-P991295 ABC-015
ABC-015 is a human monoclonal antibody (mAb) targeting KLRG1. ABC-015 can be used in multiple myeloma research.

Species: Human

C-type Lectin-like Receptors (CTLRs)  
Cancer  
/
HY-P10644 CPP9
CPP9 is a small, amphipathic, cyclic cell penetrating peptide (CPP). CPPs bind directly to the plasma membrane phospholipids and enter mammalian cells via endocytosis, followed by efficient release from the endosome. CPP9 can be used for intracellular delivery of therapeutic agents and chemical probes.
Fluorescent Dye  
Cancer  
/
HY-10227G Bortezomib (GMP)
Bortezomib (GMP) (PS-341 (GMP)) is Bortezomib (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).
Proteasome   NF-κB   Apoptosis   Autophagy   TREM receptor  
Cancer  
/
HY-P1126 Dolastatin 15
Dolastatin 15 (DLS 15), a depsipeptide derived from Dolabella auricularia, is a potent antimitotic agent structurally related to the antitubulin agent Dolastatin 10. Dolastatin 15 induces cell cycle arrest and apoptosis in multiple myeloma cells. Dolastatin 15 can be used as an ADC cytotoxin.
Microtubule/Tubulin   ADC Payloads   Apoptosis  
/
HY-P991768 Anti-Eastern equine encephalitis virus E2 protein Antibody (EEEV-3)
Anti-Eastern equine encephalitis virus E2 protein Antibody (EEEV-3) reacts with the B domain of the E2 glycoprotein on the eastern equine encephalitis virus (EEEV). Anti-Eastern equine encephalitis virus E2 protein Antibody (EEEV-3) exhibits a modest inhibition of viral attachment to the plasma membrane of the cells. Recommend Isotype Controls: Mouse IgG2c kappa, Isotype Control (HY-P99981).

Species: Virus

Virus Protease  
Viral Infection  
/
HY-Y0317I Sodium sulfate anhydrous, meets analytical specification of Ph. Eur. BP USP
Sodium sulfate anhydrous (Disodium sulfate), meets analytical specification of Ph. Eur. BP USP is an orally active multifunctional ionic salt that serves as a protein precipitant, collagen fibril bundling inducer, and chlorine-free sodium source. Sodium sulfate anhydrous, meets analytical specification of Ph. Eur. BP USP promotes collagen fibril bundling to increase matrix pore size, alters cancer cell morphology and regulates their migration direction via geometric signals, and separates plasma/serum proteins or concentrates proteins at 37°C without causing thermal denaturation. In poultry farming applications, Sodium sulfate anhydrous, meets analytical specification of Ph. Eur. BP USP improves laying performance and eggshell quality, and is safe and effective at an addition level of 0.3-1.5%, while a high concentration of 3.0% causes negative physiological effects. Sodium sulfate anhydrous, meets analytical specification of Ph. Eur. BP USP can be widely applied in scientific research on cervical cancer and related fields.
Biochemical Assay Reagents  
Cervical Cancer  
/
HY-N0667S4 L-Asparagine-4-13C monohydrate
L-Asparagine-4-13C monohydrate is the 13C-labeled L-Asparagine monohydrate (HY-W017443).L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Inflammation or Immune System Disease  
/
HY-P11053 A17 peptide
A17 peptide is a Hsp70-targeting peptide. A17 peptide binds to the ATP-binding domains of Hsp70. A17 peptide specifically inhibits the chaperone activity, thereby increasing the cells' sensitivity to apoptosis induced by chemotherapeutic agents, such as Cisplatin (HY-17394). A17 peptide can be used for anticancer chemotherapy research, such multiple myeloma.
HSP  
Cancer  
/
HY-17383S Levomefolate-13C5 calcium
Levomefolate-13C5 calcium)is the 13C-labeled Levomefolate calcium (HY-17383). Levomefolate calcium is a synthetic calcium salt of L-5-methyltetrahydrofolate and an orally active and brain-penetrant folate supplement. Levomefolate calcium incorporates into body folate pools to increase plasma and red blood cell folate levels over time. Levomefolate calcium does not significantly increase folate concentrations in breast milk. Levomefolate calcium can be used for the research of neural tube defects and megaloblastic anemia.
Isotope-Labeled Compounds   Antifolate  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-10224S Panobinostat-d4
Panobinostat-d4 is the deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].
HDAC   Autophagy   HIV   Apoptosis  
Cancer  
/
HY-D3384 AM4-65
AM4-65 is a red fluorescing styryl dye. AM4-65 can incorporate int plasma membranes to outline cell periphery and nascent cell plates.
Fluorescent Dye  
/
HY-10224S1 Panobinostat-d4 hydrochloride
Panobinostat-d4 (hydrochloride) is deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].
Isotope-Labeled Compounds   HDAC   Autophagy   HIV   Apoptosis  
Cancer  
/
HY-P10563 Noraramtide
Noraramtide (BHV-1100) is an antibody-recruiting molecule. Noraramtide binds to CD38 and recruits natural killer (NK) cells to mediate antibody-dependent cellular cytotoxicity. Noraramtide enhances the capacity of autologous cytokine-induced memory-like (CIML) NK cells to produce IFNγ and CD107a, thereby improving their cytotoxicity against multiple myeloma cells. Noraramtide can be used in the research of multiple myeloma.
CD38   IFNAR  
Leukemia/Lymphoma/Myeloma  
/
HY-P991639 BIW-8962
BIW-8962 is a humanized anti-ganglioside GM2 antibody. BIW-8962 exhibits ADCC/CDC activity against multiple myeloma cells. BIW-8962 demonstrates potent anti-tumor activity in mouse xenograft models. BIW-8962 is indicated for research in myeloma and other cancers.

Species: Human

Apoptosis  
Cancer  
/
HY-P1700 BCMA72-80
BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with great affinity to HLA-A2, used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors.
TNF Receptor  
Cancer  
/
HY-D1585 BODIPY TR methyl ester
BODIPY TR methyl ester is a lipophilic GFP Counterstain. BODIPY TR methyl ester dye readily permeates cell membranes and localizes in endomembranous organelles but not localize strongly in plasma membranes. BODIPY TR methyl ester is an excellent red fluorescent vital dye (Ex=568 nm, Em=625 nm), can be used to reveal the location and shapes of cell nuclei, the shapes of cells within embryonic tissues, as well as the bound aries of organ-forming tissues within the whole embryo.
Fluorescent Dye  
/
HY-P11257 DOTA-BP1
DOTA-BP1 is a DOTA-modified BP1 (BCMA-targeting peptide). DOTA-BP1 can be radiolabeled with [68Ga]Ga to produce a BCMA-targeting PET tracer. DOTA-BP1 can be used in the research of detecting BCMA in multiple myeloma.
Radionuclide-Drug Conjugates (RDCs)  
Cancer  
/
HY-15728S Radotinib-d6
Radotinib-d6 is deuterium labeled Radotinib (HY-15728). Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases.
Isotope-Labeled Compounds   Bcr-Abl   Apoptosis   STAT   JAK   Prion Protein  
Infection   Neurological, Eye or Ear Disease  
/
HY-16498 Tigapotide
Tigapotide (PCK-3145) is a synthetic 15-mer peptide derived from prostate-secretory protein, and acts as an antineoplastic agent. Tigapotide inhibits tumor growth, experimental bone metastasis, and malignancy-associated hypocalcemia. Tigapotide induces apoptosis in prostate cancer cells and tumors, and suppresses the growth of prostate cancer cells. Tigapotide inhibits the production of parathyroid hormone-related protein (PTHrP) in tumors and plasma. Tigapotide reduces plasma calcium levels in hypercalcemic tumor-bearing rats. Tigapotide is applicable for the research of prostate cancer and malignancy-associated hypercalcemia.
Apoptosis   PTHR  
Prostate Cancer   Hypercalcemia  
/
HY-P991954 GT103
GT103 is a human-derived monoclonal antibody targeting complement factor H (CFH). GT103 binds to a conformationally distinct epitope of CFH on tumor cells. GT103 activates the classical complement pathway, induces complement-dependent cytotoxicity, and triggers antibody-dependent cellular phagocytosis (ADCP) of tumor cells. GT103 increases calreticulin translocation to tumor cell plasma membranes. GT103 mediates B-cell activation via Syk kinase phosphorylation. GT103 inhibits tumor growth and metastasis in animal models. GT103 can be used for the research of non-small cell lung cancer.

Species: Human

Complement System   Syk  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer  
/
HY-W845197 L-Asparagine-15N2
L-Asparagine-15N2 ((-)-Asparagine-15N2) is the 15N-labeled L-Asparagine (HY-N0667). L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   DNA/RNA Synthesis   Apoptosis   Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-138146 4-Dehydrowithaferin A
4-Dehydrowithaferin A is the analogue of withaferin A. Withaferin A is a withanolide isolated from Withania somnifera. 4-Dehydrowithaferin A has the potential for the research of multiple myeloma.
Drug Derivative  
Cancer  
/
HY-125490 Shermilamine B
Shermilamine B, a pyridoacridine alkaloid, exhibits potent anticancer activity in multiple myeloma cell lines.

Source: Tunicate Eudistoma sp.

Others  
Cancer  
/
HY-16050R Plitidepsin (Standard)
Plitidepsin (Standard) is the analytical standard of Plitidepsin. This product is intended for research and analytical applications. Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( KD=80 nM). Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC90 of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research.
Reference Standards   DNA/RNA Synthesis   SARS-CoV  
Infection  
/
HY-D2263 BODIPY-cholesterol conjugate-3
BODIPY-cholesterol conjugate-3 (compound 7) is a cholesterol analogue with a fluorescent BODIPY group. BODIPY-cholesterol conjugate-3 can be used to simultaneously visualize multiple cholesterol pools in cells, as it is primarily localized to the plasma membrane.
Fluorescent Dye  
/
HY-N7122R Thymopentin (Standard)
Thymopentin is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs).
Reference Standards   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease  
/
HY-N15423 Acrophylline
Acrophylline is an antiallergic compound. Acrophylline inhibits mast cell degranulation. Acrophylline reduces the plasma leakage in mouse ear in a passive cutaneous anaphylactic (PCA) reaction. Acrophylline is an alkaloid can be isolated from acronychia haplophylla.
Others  
Inflammation or Immune System Disease  
/
HY-100168R BAPTA (Standard)
BAPTA (Standard) is the analytical standard of BAPTA. This product is intended for research and analytical applications. BBAPTA is a selective and cell-impermeant chelator for calcium. BAPTA, as calcium indicator, has high selectivity against magnesium and calcium. BAPTA is widely used as an intracellular buffer for investigating the effects of Ca2+ release from intracellular stores or influx via Ca2+-permeable channels in the plasma membrane. BAPTA can also inhibit phospholipase C activity independently of their role as Ca2+ chelators.
Reference Standards   Phospholipase  
/
HY-P991221 ALD1613
ALD1613 is a potent neutralizing monoclonal antibody against adrenocorticotropic hormone (ACTH). ALD1613 neutralizes ACTH-induced signaling and inhibits ACTH-induced cyclic AMP accumulation in a mouse adrenal cell line (Y1) via all five melanocortin receptors. ALD1613 significantly reduces plasma corticosterone levels in wild-type rats. ALD1613 can be used in the study of diseases associated with elevated ACTH levels.

Species: Human

Melanocortin Receptor  
Metabolic or Endocrine Disease  
/
HY-P991898 IASO-782
IASO-782 (RD126) is a fully human monoclonal antibody targeting human CD19. The Fc segment of IASO-782 is mutated to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) while maintaining the integrity of other Fc segment functions, such as ADCP. IASO-782 effectively eliminates CD19+ B cells, plasmablasts, and some plasma cells, thereby reducing or completely eliminating autoreactive antibodies produced by these cells. IASO-782 can be used for the study of immune thrombocytopenic purpura (ITP), warm autoimmune hemolytic anemia (wAIHA) and systemic lupus erythematosus (SLE).

Species: Human

CD19  
Systemic Lupus Erythematosus  
/
HY-120885 (+)-Oxanthromicin
(+)-Oxanthromicin (Compound 1) mislocalizes the oncogenic mutant K-Ras from the plasma membrane of intact Madin-Darby canine kidney (MDCK) cells, and exhibits thereby antitumor efficacy.

Source: Streptomyces sp.

Ras  
Cancer  
/
HY-141636S 1-PalMitoyl-2-arachidoyllecithin-d9-1
1-PalMitoyl-2-arachidoyllecithin-d9-1 (1-Palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine-d9-1) is deuterium labeled 1-PalMitoyl-2-arachidoyllecithin. 1-Palmitoyl-2-arachidonoyl-sn-glycero-3-PC (PAPC) is a phospholipid containing palmitic acid (16:0) and arachidonic acid (20:4) at the sn-1 and sn-2 positions, respectively, that is found in biological membranes. PAPC is oxidized in vivo, and its oxidation products are involved in chronic inflammation and vascular disease. PAPC has been used to study signaling of oxidized phospholipids. Levels of PAPC are decreased in isolated human multiple myeloma cells.
Isotope-Labeled Compounds   Endogenous Metabolite  
Blood or Cardio-cerebrovascular Disease  
/
HY-114457 Phosphatidylinositol 4,5-bisphosphate
Phosphatidylinositol 4,5-bisphosphate (L-alpha-Phosphatidylinositol-4,5-bisphosphate) is a plasma membrane lipid that is enriched in the cytoplasmic leaflet of the plasma membrane. Phosphatidylinositol 4,5-bisphosphate serves as a substrate for phospholipase C and class I PI3K, generating diacylglycerol, inositol (1,4,5)-trisphosphate, and phosphatidylinositol (3,4,5)-trisphosphate. Phosphatidylinositol 4,5-bisphosphate contributes to lamellipodial protrusion, directional cell migration, focal adhesion lipid generation, and trafficking of the GABAA receptor. Phosphatidylinositol 4,5-bisphosphate can be used in research related to acute lung injury and pulmonary edema.
Phospholipase  
Acute Lung Injury  
/
HY-D2376 BH-Vis
BH-Vis is a two-photon fluorescent probe that inhibits cell plasma membrane (CPM). BH-Vis has great potential to accurately identify pyroptosis at the cellular level during AAA development in the mouse abdominal aortic aneurysm AAA model.
Fluorescent Dye  
Cancer  
/
HY-113202S Stearoyl-L-carnitine-d3
Stearoyl-L-carnitine-d3 is the deuterium labeled Stearoylcarnitine. Stearoylcarnitine, a fatty ester lipid molecule, is an endogenous metabolite. Stearoylcarnitine can be used as PKC inhibitor. Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoylcarnitine inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoylcarnitine acts as a metabolomics biomarker for Parkinson’s disease. Stearoylcarnitine is a less potent inhibitor of GlyT2.
Isotope-Labeled Compounds   Endogenous Metabolite   PKC   GlyT  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-100168BR BAPTA tetrapotassium (Standard)
BAPTA tetrapotassium (Standard) is the analytical standard of BAPTA tetrapotassium (HY-100168B). This product is intended for research and analytical applications. BAPTA tetrapotassium is a selective and cell-impermeant chelator for calcium. BAPTA tetrapotassium, as calcium indicator, has high selectivity against magnesium and calcium. BAPTA tetrapotassium is widely used as an intracellular buffer for investigating the effects of Ca2+ release from intracellular stores or influx via Ca2+-permeable channels in the plasma membrane. BAPTA tetrapotassium can also inhibit phospholipase C activity independently of their role as Ca2+ chelators.
Reference Standards   Phospholipase  
/
HY-N19899 Phaeosphaeride A
Phaeosphaeride A is a STAT3 inhibitor with an IC50 of 0.61 mM against human STAT3. It exhibits higher selectivity for STAT3 over STAT1 and STAT5. Phaeosphaeride A inhibits the binding of STAT3 to DNA, STAT3-dependent transcriptional activity, as well as IL-6-induced phosphorylation and signaling of STAT3. Phaeosphaeride A activates the JNK, p38, Akt, CREB and STAT5A/B signaling pathways. Phaeosphaeride A induces oxidative stress (ROS), exerts antiproliferative and growth-inhibitory effects in cancer cells, and shows low cytotoxicity toward non-cancerous cells. Phaeosphaeride A is a phytotoxin and a weak animal toxin, with no antimicrobial activity against tested bacteria and fungi. Phaeosphaeride A can be used in research related to conditions such as cervical cancer and multiple myeloma, as well as weed infestations.

Source: Phaeosphaeria avenara

STAT   JNK   p38 MAPK   Akt   Reactive Oxygen Species (ROS)  
Cervical Cancer   Multiple Myeloma  
/
HY-N0176S6 Dihydroartemisinin-d
Dihydroartemisinin-d (Dihydroqinghaosu-d) is the d-labeled Dihydroartemisinin (HY-N0176). Dihydroartemisinin is an orally active metabolite of rtemisinin (HY-B0094) and antimalarial agent. Dihydroartemisinin induces Autophagy by inhibiting NF-κB activation. Dihydroartemisinin promotes ROS accumulation. Dihydroartemisinin exhibits anticancer activity in esophageal cancer cells. Dihydroartemisinin shows schistosomicidal activity against juvenile and adult worms of Schistosoma japonicum, reduces worm burden, and displays antiparasitic activity. Dihydroartemisinin can be used in research related to multiple myeloma, promyelocytic leukemia, esophageal cancer, and Schistosoma japonicum infection.
Isotope-Labeled Compounds   Parasite   NF-κB   Autophagy   Reactive Oxygen Species (ROS)   Drug Metabolite  
Breast Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Multiple Myeloma   Plasmodium Infection   Systemic Lupus Erythematosus   Obesity  
/
HY-N0667S1 L-Asparagine-15N2,d8
L-Asparagine-15N2,d8 is the 15N- and deuterium labeled L-Asparagine (HY-N0667). L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Inflammation or Immune System Disease  
/
HY-N0667S L-Asparagine-13C4,15N2,d8
L-Asparagine-13C4,15N2,d8 is the 13C-labeled and 15N-labeled L-Asparagine (HY-N0667). L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Inflammation or Immune System Disease  
/
HY-N0815R Resibufogenin (Standard)
Resibufogenin (Standard) is the analytical standard of Resibufogenin. This product is intended for research and analytical applications. Resibufogenin is an orally active anticancer agent. Resibufogenin can be extracted from toad venom. Resibufogenin blocks signaling pathways such as PI3K/Akt, NF-κB, AP-1, activates GSK-3β, and regulates cyclin D1. Resibufogenin can activate central neurons. Resibufogenin has anti-inflammatory activity. Resibufogenin has anti-tumor effects on a variety of tumors such as multiple myeloma, renal cancer, colorectal cancer, pancreatic cancer, and glioma.
Reference Standards   Others  
Cancer  
/
HY-W017443S1 L-Asparagine-amide-15N monohydrate
L-Asparagine-amide-15N monohydrate is the 15N-labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-B0633E Hyaluronic acid, low endotoxin
Hyaluronic acid, low endotoxin (Hyaluronan, low endotoxin) is a biopolymer composed of repeating disaccharide units containing low levels of endotoxin. Hyaluronic acid is a major component of the extracellular matrix (ECM). It is synthesized on the plasma membrane. Hyaluronic acid exerts its effects by binding to receptors CD44 and RHAMM. Hyaluronic acid activates PI3K-Akt signaling. Hyaluronic acid also enhances cell invasion and angiogenesis by promoting or stimulating the binding of proteolytic MMP-9 to the cell surface. Elevated hyaluronic acid levels are associated with tumor cell growth, adhesion, migration, invasion, and angiogenesis in digestive system cancers. Hyaluronic acid is involved in tissue remodeling and rapid cell proliferation in several physiological processes, including embryonic morphogenesis and wound healing. Hyaluronic acid can be used as a regulator of cancer-associated lymphangiogenesis. Hyaluronic acid can be used as a drug delivery carrier for sodium butyrate, enhancing its anti-proliferative activity against breast cancer cell lines. Hyaluronic acid can lubricate the corneal endothelium. Hyaluronic acid can improve tissue hydration and enhance the resistance of cells to mechanical damage. Hyaluronic acid has been conjugated with antibodies to ensure that the active compound continues to exert its effects at the site of inflammation. Hyaluronic acid can be used in research in the fields of osteoarthritis, ophthalmology, cosmetic dermatology, oncology, and liver diseases.
Endogenous Metabolite   CD44   Bacterial   Akt   PI3K  
Cancer   Inflammation or Immune System Disease   Visual System Disease   Liver Disease   Osteoarthritis  
/
HY-10227S Bortezomib-d8
Bortezomib-d8 is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).
Isotope-Labeled Compounds   Proteasome   NF-κB   Apoptosis   Autophagy   TREM receptor  
Cancer  
/
HY-W110790 Bromocresol purple sodium
Bromocresol purple sodium is a pH indicator, whose color changes from yellow to purple when the pH increases from 5.2 to 6.8. Bromocresol purple sodium can be used for detecting yeast cells with plasma membrane damage and measuring serum albumin concentrations.
Biochemical Assay Reagents  
/
HY-P991183 SAR-442257
SAR-442257 is a trispecific T-cell engager and monoclonal antibody that binds to CD38, CD3 and CD28. SAR-442257 can target and bind to CD3 and CD28 on T cells, as well as CD38 expressed on tumor cells. SAR-442257 mediates T-cell activation, enhances T-cell activity, induces T-cell degranulation, and drives cytotoxicity against multiple myeloma cells. SAR-442257 functions via CD38 expression, and its in vitro activity correlates with CD38 expression on the surface of multiple myeloma cells. SAR-442257 can be used in studies related to multiple myeloma and relapsed/refractory multiple myeloma.

Species: Human

CD28   CD38   CD3  
Multiple Myeloma  
/
HY-122357 Bestim
Bestim (γ-Glu-Trp) is a dipeptide, which exhibits high affinity to murine peritoneal macrophages, thymocytes, and plasma membranes isolated from these cells, with Kds of 3.1, 2.1, 18.6 and 16.7 nM, respectively. Bestim inhibits adenylate cyclase in the membranes of murine macrophages and thymocytes. Bestim exhibits immunomodulatory efficacy.
Adenylate Cyclase  
Inflammation or Immune System Disease  
/
HY-P990175 Anti-Mouse OX40L/CD134L Antibody (RM134L)
Anti-Mouse OX40L/CD134L Antibody (RM134L) is an anti-mouse OX40L/CD134L IgG2b monoclonal antibody. Anti-Mouse OX40L/CD134L Antibody (RM134L) reduces immune response by inhibiting the OX40/OX40L signaling pathway. Anti-Mouse OX40L/CD134L Antibody (RM134L) can inhibit plasma cell differentiation and antibody secretion. Anti-Mouse OX40L/CD134L Antibody (RM134L) can prolong the survival time of cell transplantation by inhibiting CD4+ T cells. Anti-Mouse OX40L/CD134L Antibody (RM134L) can be used for researches on inflammation and cancer such as graft versus host disease (GVHD), allergic reaction, lupus nephritis and hepatocellular carcinoma (HCC).

Species: Mouse

Orexin Receptor (OX Receptor)  
Cancer   Inflammation or Immune System Disease  
/
HY-114146 CID 1375606
CID 1375606 is a surrogate agonist of orphan G protein-coupled receptor GPR27.
Orphan GPCR  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P99559 Tilogotamab
Tilogotamab is an agonistic hexamer formation-enhanced mixture of two antibodies that target two separate epitopes on death receptor type 5 (DR5). Tilogotamab specifically binds to and activates DR5. Tilogotamab can be used for the research of multiple myeloma (MM).

Species: Human

Others  
Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
/
HY-W010736 1,2-Dipalmitoyl-sn-glycerol
1,2-Dipalmitoyl-sn-glycerol is a diacylglycerol that activates PKC. 1,2-Dipalmitoyl-sn-glycerol promotes GLUT4 translocation to the cell surface and recruitment to the plasma membrane of adipocytes. 1,2-Dipalmitoyl-sn-glycerol can be used in research on type 2 diabetes.
PKC   GLUT  
Type 2 Diabetes  
/
HY-P10649A CPP12 TFA
CPP12 TFA is a small, amphipathic, cyclic cell-penetrating peptide (CPP). CPP12 TFA binds directly to plasma membrane phospholipids, enters mammalian cells via endocytosis, and then efficiently escapes from endosomes. CPP12 TFA can be used for the intracellular delivery of drugs and chemical probes.
Others  
Cancer  
/
HY-P991490 ISB2001
ISB2001 is a trispecific antibody targeting CD38, CD3 and BCMA. ISB2001 effectively counteracts tumor immune escape mechanisms caused by antigen downregulation, antigen loss, soluble factor competition and other factors. ISB2001 is applicable to relevant research on multiple myeloma and relapsed/refractory multiple myeloma.

Species: Human

CD38   CD3   TNF Receptor  
Cancer  
/
HY-P10644A CPP9 TFA
CPP9 TFA is a small, amphipathic, cyclic cell penetrating peptide (CPP). CPPs bind directly to the plasma membrane phospholipids and enter mammalian cells via endocytosis, followed by efficient release from the endosome. CPP9 TFA can be used for intracellular delivery of therapeutic agents and chemical probes.
Others  
Cancer  
/
HY-D0920 TOTO-3
TOTO-3 is a cyanine nucleic acid intercalating fluorescent probe that binds to both RNA and DNA (Ex=642 nm, Em=660 nm). TOTO-3 cannot enter intact cells, but can penetrate cells with permeabilized plasma membranes, staining cytoplasmic RNA and nucleoli to distinguish intact cells from damaged ones. TOTO-3 is taken up by macrophages in an ultrasound-independent manner. TOTO-3 accumulates in tumor cells via ultrasound-mediated enhancement of plasma membrane permeability. TOTO-3 supports optical imaging for real-time assessment of plasma membrane integrity, nucleic acid detection, and monitoring of ultrasound-mediated intracellular delivery processes. TOTO-3 is applicable to studies related to rectal cancer.
Fluorescent Dye  
Colorectal Cancer  
/
HY-W010448 Imidazol-1-yl-acetic acid
Imidazol-1-yl-acetic acid is a BRS-3 agonist that mediates anorectic effects through activation of orphan G protein-coupled receptors (Orphan GPCR) in peripheral tissues; it also serves as a green, water-soluble, recyclable bifunctional organocatalyst for transformations such as Biginelli multicomponent reactions and epoxide ring opening. Imidazol-1-yl-acetic acid is used in the study of obesity.
Bombesin Receptor   Orphan GPCR  
Obesity  
/
HY-P990095 Vonsetamig
Vonsetamig (REGN5459) is a human bispecific antibody targeting BCMA and CD3. Vonsetamig triggers T-cell activation, induces plasma cell depletion, and triggers low-level cytokine release. Vonsetamig can be used for the research of relapsed/refractory multiple myeloma.

Species: Human

CD3   TNF Receptor  
Multiple Myeloma  
/
HY-DY1057 TMA-DPH (solution)
TMA-DPH (solution) is a hydrophobic fluorescent membrane probe (Ex=355 nm; Em=430 nm). TMA-DPH is able to anchor on the cell surface and localize to different regions of the phospholipid bilayer. By analyzing the fluorescence polarization values of TMA-DPH in the plasma membrane and membrane substructures, the fluidity of the cell membrane can be determined.
Solvent and concentration: DMSO: 10 mM
Fluorescent Dye  
/
HY-N0176R Dihydroartemisinin (Standard)
Dihydroartemisinin (Standard) (Dihydroqinghaosu (Standard)) is the analytical standard of Dihydroartemisinin (HY-N0176). This product is intended for research and analytical applications. Dihydroartemisinin is an orally active metabolite of rtemisinin (HY-B0094) and antimalarial agent. Dihydroartemisinin induces Autophagy by inhibiting NF-κB activation. Dihydroartemisinin promotes ROS accumulation. Dihydroartemisinin exhibits anticancer activity in esophageal cancer cells. Dihydroartemisinin shows schistosomicidal activity against juvenile and adult worms of Schistosoma japonicum, reduces worm burden, and displays antiparasitic activity. Dihydroartemisinin can be used in research related to multiple myeloma, promyelocytic leukemia, esophageal cancer, and Schistosoma japonicum infection.
Reference Standards   Parasite   NF-κB   Autophagy   Reactive Oxygen Species (ROS)   Drug Metabolite  
Breast Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Multiple Myeloma   Plasmodium Infection   Systemic Lupus Erythematosus   Obesity  
/
HY-N4184 Licoflavone B
Licoflavone B is an orally active flavonoid, with IC50 values of 23.78 μM and 31.5 μM against SmATPase and SmADPase of Schistosoma mansoni, respectively. Licoflavone B selectively targets viral RdRp, inhibits viral replication, and reduces the expression levels of viral NP and PB2. Licoflavone B inhibits c-Myc expression and suppresses cancer cell proliferation. Licoflavone B disrupts the tegument of worms, reduces egg production, and induces the death of adult Schistosoma mansoni. Licoflavone B blocks the activation of the MAPK pathway, maintains colonic barrier integrity, inhibits colonic cell apoptosis, and reshapes the gut microbiota. Licoflavone B can be used in research related to influenza, multiple myeloma, schistosomiasis, and ulcerative colitis.
Parasite   Influenza Virus   ATP Synthase   c-Myc   p38 MAPK   Apoptosis  
Multiple Myeloma   Influenza Virus Infection   Schistosoma Japonicum Infection   Ulcerative Colitis  
/
HY-163087 PT-91
PT-91 is an agonist of GPR27. PT-91 exhibits high metabolic stability and brain exposure in mice.
Orphan GPCR  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-N0667S3 L-Asparagine-13C4 monohydrate
L-Asparagine-13C4 monohydrate is the 13C-labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Inflammation or Immune System Disease  
/
HY-156354 GPR61 Inverse agonist 1
GPR61 Inverse agonist 1 (Compound 1) is a GPR61 inverse agonist (IC50: 11 nM). GPR61 Inverse agonist 1 can be used for research of disorders of metabolism and body weight, such as obesity and cachexia.
Orphan GPCR  
Metabolic or Endocrine Disease  
/
HY-W087928 Bromocresol purple
Bromocresol purple is a pH indicator, whose color changes from yellow to purple when the pH increases from 5.2 to 6.8. Bromocresol purple can be used for detecting yeast cells with plasma membrane damage and measuring serum albumin concentrations.
Biochemical Assay Reagents  
/
HY-P991155 Ramantamig
Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma.

Species: Human

CD3   TNF Receptor  
Multiple Myeloma  
/
HY-N4202 Dihydrorotenone
Dihydrorotenone is an insecticide and irreversible inhibitor of mitochondrial complex I. Dihydrorotenone may induce Parkinson's disease. Dihydrorotenone induces apoptosis in human plasma cells by triggering endoplasmic reticulum stress and activating the p38 signaling pathway. The oral LD50 of dihydrorotenone in rats is approximately 2.5 g/kg. Dihydrorotenone exhibits insecticide activity and cytotoxicity to plasma cells. Dihydrorotenone can be used to establish animal models of Parkinson's disease, safety assessment of natural pesticides, and potential cancer chemoprevention studies.
Environmental Pollutants   p38 MAPK   Apoptosis   Insecticide  
Digestive System Disease   Lung Cancer   Pain   Digestive System Inflammation   Parkinson's Disease  
/
HY-155417 GPR34 receptor antagonist 3
GPR34 receptor antagonist 3 (Compound 5e) is a class of GRP34 antagonists, IC50 is 0.680 μM. GPR34 receptor antagonist 3 inhibited ERK1/2 phosphorylation induced by lysophosphatidylserine in a dose-dependent way without obvious cytotoxicity. GPR34 receptor antagonist 3 shows antisensory activity in mouse neuropathic pain model .
Orphan GPCR   ERK  
Colorectal Cancer   Prostate Cancer   Liver Cancer   Pain   Obesity  
/
HY-155318A GPR3 agonist-2
GPR3 agonist-2(compound 32) is a potent full agonist of G protein-coupled receptor 3, with the IC50of 260 nM.
Orphan GPCR  
Metabolic or Endocrine Disease  
/
HY-B0896 Triacetin
Triacetin (Glyceryl triacetate) is a synthetic compound that is a triester of glycerol and acetic acid, orally active. Triacetin increases acetate bioavailability in glioma cells. Triacetin induces glioma cell growth arrest and Apoptosis. Triacetin freely crosses the blood brain barrier/plasma membrane. Triacetin increases histone acetylation and enhances Temozolomide (HY-17364) (TMZ) chemotherapeutic efficacy .
Environmental Pollutants   Endogenous Metabolite   Fungal  
Breast Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Digestive System Inflammation  
/
HY-P3522 REDV
REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion. REDV is used to study the effects of gene vectors containing REDV on cells.
Integrin  
Blood or Cardio-cerebrovascular Disease  
/
HY-N15721 Tryptophan-cholic acid
Tryptophan-cholic acid (Trp-CA) is a microbial amino acid-conjugated bile acid that acts as an endogenous ligand and agonist (EC50=9.6 μM) for the orphan G protein-coupled receptor (GPCR) MRGPRE (Mas-related G protein-coupled receptor family member E). Tryptophan-cholic acid is orally effective but has poor oral absorption and does not cross the blood-brain barrier. Tryptophan-cholic acid promotes the secretion of glucagon-like peptide GLP-1, thereby improving glucose tolerance in diabetic mice. Tryptophan-cholic acid improves glucose tolerance, promotes insulin secretion, and alleviates high-fat diet-induced hepatic steatosis without causing pruritus side effects. Tryptophan-cholic acid is primarily used in research on type 2 diabetes (T2D).
Orphan GPCR   GLP Receptor  
Type 2 Diabetes  
/
HY-156815 YL-365
YL-365 is a potent and selective GPR34 antagonist with an IC50 of 17 nM. YL-365 binds to a portion of the orthosteric binding pocket of GPR34 and induces allosteric changes that stabilize the receptor in an inactive conformation. YL-365 down-regulates expression of the proinflammatory gene iNOS in M1 microglia and suppresses proinflammatory responses. YL-365 reduces mechanical allodynia in a dose-dependent manner in a mouse model of neuropathic pain. YL-365 can be used for the research of neuropathic pain.
Orphan GPCR  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-P99616 Felzartamab
Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research.

Species: Human

CD38  
Cancer  
/
HY-P3160C Fibronectin, bovine plasma
Fibronectin, bovine plasma is a fibronectin derived from bovine plasma. Fibronectin is an extracellular matrix protein that is upregulated and essential in many developmental processes, and also exists in the pathological progression of tissues and wound healing. Fibronectin specifically binds to a large number of molecules, including other components of the extracellular matrix, signaling molecules and cell adhesion molecules. The interaction between cells and fibronectin leads to bidirectional crosstalk, which regulates cell functions and induces cell-dependent changes in the extracellular matrix. Fibronectin, bovine plasma inhibits the production of bovine leukemia virus (BLV) p24 core protein in naturally infected bovine peripheral blood mononuclear cells.
Biochemical Assay Reagents  
Viral Infection  
/
HY-P9989 Linvoseltamab
Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody that specifically binds to B cell maturation antigen (BCMA) and CD3 of T cells, thereby directing T cells to multiple myeloma (MM) cells expressing BCMA and activating T cells to kill tumor cells. Linvoseltamab can be used in research of relapsed/refractory multiple myeloma (RRMM).

Species: Human

CD3   TNF Receptor  
Cancer  
/
HY-NP138 NP-OVAL (Ovalbumin)
NP-OVAL (Ovalbumin) is a complex formed by 4-Hydroxy-3-nitrophenylacetyl (NP, a hapten) with Ovalbumin (OVAL, a carrier protein). NP-OVAL (Ovalbumin) can induce specific immune responses and NP-specific antibodies production. NP-OVAL (Ovalbumin) can accelerate the construction of multiple myeloma models.
Biochemical Assay Reagents  
Inflammation or Immune System Disease   Multiple Myeloma  
/
HY-P75906 LECT1 Protein, Human (HEK293, Fc)
The LECT1 protein is a bifunctional growth regulator that stimulates the growth of cultured chondrocytes via FGF, thereby promoting cartilage expansion. Instead, it inhibits vascular endothelial cell growth, in contrast to its effect on endothelial proliferation. LECT1 Protein, Human (HEK293, Fc) is the recombinant human-derived LECT1 protein, expressed by HEK293 , with N-hFc labeled tag.

Species: Human; Source: HEK293

/
HY-P702074 WHSC1 Protein, Human (sf9, His, StrepⅡ)
WHSC1 Protein, Human (sf9, His, Strep) is the recombinant human-derived WHSC1 protein, expressed by sf9 insect cells, with N-Strep, N-8*His labeled tag.

Species: Human; Source: Sf9 insect cells

/
HY-P82663 MUM1 Antibody (YA2408)
MUM1 Antibody (YA2408) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MUM1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P87049 REIIBP/NSD2 Antibody (YA6742)
REIIBP/NSD2 Antibody (YA6742) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to REIIBP/NSD2.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85920 MUM1 Antibody (YA5612)
MUM1 Antibody (YA5612) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to MUM1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P812006 C1orf35 Antibody(YA10477)
C1orf35 Antibody(YA10477) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to C1orf35.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P812006A C1orf35 Antibody(YA10477) (PBS only)
C1orf35 Antibody(YA10477) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to C1orf35.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P86042 MUM1 Antibody (YA5734)
MUM1 Antibody (YA5734) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to MUM1.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/

Keywords

BCMA CAR-T | multiple myeloma | idecabtagene vicleucel | ciltacabtagene autoleucel | antigen escape | plasma cells